Niclosamide from an anthelmintic drug to a promising adjuvant therapy for diabetic kidney disease: randomized clinical trial

Table 2 Summary of the primary outcomes

	Niclosamide arm n = 30	Control arm n = 30	P value between arms
UACR (mg/g)
Baseline	225.5 ± 83	247.7 ± 80	0.299
After 6 months	170.9 ± 72	271.3 ± 86.6	< 0.0001*
Percent change between the 2 points	− 24.2 ± 15	11.1 ± 19	< 0.0001*
P Value within each arm	< 0.0001*	0.005*
Serum creatinine (mg/dL)
Baseline	1.1 ± 0.13	± 0.31.1	0.503
After 6 months	1.08 ± 0.09	1.2 ± 0.2	0.069*
Percent change between the 2 points	− 1 ± 8.2	5 ± 9.6	0.017*
P Value within each arm	0.245	0.014*
eGFR (mL/min/1.73 m²)
Baseline	84.7 ± 15	81.9 ± 18.7	0.528
After 6 months	85.4 ± 13.8	78 ± 14.1	0.040*
Percent change between the 2 points	1.5 ± 7.7	− 3.5 ± 8.8	0.029*
P Value within each arm	0.583	0.02*

Values are expressed as mean ± SD
UACR, urinary albumin to creatinine ratio; eGFR, estimated Glomerular filtration rate
*Significant difference (P < 0.05)

ISSN: 1758-5996